Plasma levels of lipoprotein [a] (Lp[a]) are associated with increased risk of coronary artery disease and show an inverse correlation with apolipoprotein[a] (apo [a]) molecular weight. We determined Lp [a] levels and apo [a] phenotypes in 171 cases with preclinical extracranial carotid atherosclerosis as ascertained by B-mode ultrasound and in 274 control subjects free of carotid atherosclerosis. Lp [a] protein levels measured by enzyme-linked immunosorbent assay ranged from 4 to 361 /ig/mL in cases and from 2 to 392 jug/mL in controls, but median levels of Lp[a] were higher in cases than in controls (51 Aig/mL versus 33 /ig/mL, P<.003). In both groups, all 11 apo [a] 
A ssociations between elevated plasma concentra-/ \ tions of lipoprotein[a] (Lp[a]) and symptomatic -Z A . atherosclerosis such as coronary artery disease (CAD) and cerebrovascular disease have been established in numerous studies employing various designs and analytic approaches. 15 Cross-sectional studies have established the relation between plasma Lp[a] levels and their relevance for various atherosclerotic diseases (reviewed in References 6 and 7). That elevated plasma levels of Lp [a] confer an increased risk for CAD has also been demonstrated in one prospective study. 8 However, no association of Lp [a] with cardiac end points has been found in the Helsinki Heart Study cohort. 9 Thus, the association of Lp[a] levels with incident CAD is currently equivocal.
quences that encode the number of apo[a] kringle 2 units as well as additional sequence variation at the apo[a] gene locus are responsible for the control of plasma Lp[a] levels.
We previously showed that mean plasma Lp[a] levels were significantly higher in subjects with asymptomatic thickening of extracranial carotid arteries when compared with control subjects ("controls") free of carotid atherosclerosis. 25 Because of the relations among apo[a] size, Lp[a] level, and apo [a] phenotype with CAD, 2627 we hypothesized that the distribution of apofa] phenotypes might differ between carotid cases and controls. We therefore performed apo [a] phenotyping in 171 carotid cases and 274 controls. While there was an inverse correlation of apofa] size with Lpfa] levels in both cases and controls, the distribution of apofa] phenotypes was similar between the two groups, even though median Lpfa] levels were higher in cases than in controls. In fact, in the majority of Lpfa] phenotypes, cases exhibited higher Lpfa] levels than controls. Thus, undetected environmental factors or, more likely, sequence heterogeneity of the apofa] gene that is unrelated to the number of kringle type 2 repeats may be an important determinant of the elevated plasma Lpfa] levels in the cases with carotid atherosclerosis studied here.
Methods

Study Population
Cases and controls were selected from the Atherosclerosis Risk in Communities (ARIC) Study, a prospective, multicenter investigation of atherosclerosis and its clinical sequelae in women and men aged 45 to 64 years. Approximately 16 000 residents were recruited, 4000 in each of four communities: Forsyth County, NC; the city of Jackson, Miss; the northwestern suburbs of Minneapolis, Minn; and Washington County, Md. The cohort was selected to represent a probability sample of residents living in that community, except for the Jackson sample, which contained only black residents. The general design of the ARIC Study has been described elsewhere. 28 Carotid wall thickness was measured by B-mode ultrasonography 29 and the technique of Pignoli et al. 30 Subjects were designated as "cases" if the maximum carotid arterial wall thickness was >2.5 mm or if there was bilateral thickening above the ~90th percentile of the ARIC Study cohort distribution (corresponding to 1.7 mm in the internal carotid, 1.8 mm in the carotid bifurcation, and 1.6 mm in the common carotid). Subjects were designated as controls if the maximum wall thickness was <75th percentile at the near and far walls of each of the carotid segments and popliteal arteries. 31 Controls were group-matched to cases by gender, race, field center, 10-year age group, and time of examination. Cases and controls were required to meet minimum visualization criteria of arterial wall boundaries on ultrasound. Only the data for whites were used in this analysis to avoid confounding influences of race on the relation between Lpfa] levels and apofa] phenotypes. 32 Other exclusion criteria for case-control selection were (1) evidence of symptomatic cardiovascular or cerebrovascular disease defined by a history of angina on effort, physician-diagnosed heart attack, transient ischemic attack or stroke, or intermittent claudication; (2) use of lipid-altering medication, such as /3-blockers, hypolipidemics, or thyroid medication; (3) use of oral contraceptives in premenopausal women; (4) insulindependent diabetes mellitus; (5) chronic renal or liver disease; and (6) hypertriglyceridemia defined as fasting triglyceride levels >400 mg/dL. Thus, cases may be considered as a simple random sample of cases (with certain exclusions and assuming random response), while controls are a stratified random sample. Hence, control means and proportions do not estimate population means and proportions but are more like estimates adjusted by the distribution among cases for the levels of the stratifying variables. Sitting blood pressure was measured after a 5-minute rest, three times, using a random-zero sphygmomanometer. The systolic blood pressure measurement used was the average of the second and third readings. Hypertension was defined by a systolic or diastolic blood pressure >160 or 95, respectively, or by current use of antihypertensive medication. Body mass index (in kilograms per meters squared) was calculated from measurements of weight (to the nearest pound) or height (to the nearest centimeter).
Laboratory Measurements
Venous blood was collected after a 12-hour fast into tubes containing EDTA. Plasma was separated by centrifugation at 4°C. Aliquots were stored at each field center at -70°C and shipped on dry ice at weekly intervals to the ARIC Central Lipid Laboratory. Specimens were stored at -70°C until analyzed. Total plasma cholesterol 33 and triglyceride 34 were measured enzymatically on a Cobas-Fara centrifugal analyzer (Roche Diagnostics, Montclair, NJ) with the respective enzymatic kits (catalog Nos. 236691 and 701912, Boehringer Mannheim Diagnostics, Indianapolis, Ind). Highdensity lipoprotein (HDL) cholesterol was determined by measuring cholesterol in the supernatant liquid after precipitation of the plasma with magnesium chloride and dextran sulfate. 35 Low-density lipoprotein (LDL) cholesterol levels were calculated according to Friedewald et al. 36 Apolipoprotein A-I and B levels were determined by a radioimmunoassay. 37 - 38 Plasma levels of Lpfa] were determined by a double-antibody enzymelinked immunoassay (ELISA) described previously. 39 In brief, the immunoglobulin G (IgG) fraction of goat anti-human apofa] antisera was bound to the surface of microtiter plates to capture the Lpfa] in plasma samples and in the standard. For detection of bound Lpfa], rabbit anti-human apofa] serum was used, which was quantified using a goat anti-rabbit IgG peroxidase conjugate. Lpfa], purified as described by Gaubatz et al, 39 was used as a primary standard. Criteria of purity included the absence of all apolipoproteins except apoB and apofa], as judged by polyacrylamide gel electrophoresis (PAGE) and Western blotting with cognate antibodies, and the absence of LDL as judged by doubledecker immunoelectrophoresis. Lpfa] levels are given in micrograms per milliliter and represent the total protein moiety of Lpfa], including apofa] and associated apoB. With this method, Lpfa] protein was detectable in the plasma of all subjects. For normal Lpfa] protein levels in the range of 1 to 10 mg/dL, the contribution of plasminogen to Lpfa] levels was negligible.
For internal quality control of lipid and apolipoprotein measurements, control pools were used. The coefficients of laboratory variation were 2.5% for cholesterol, 2.7% for triglyceride, 3.7% for HDL cholesterol, 5.2% for LDL cholesterol, 9% for apoA-1,9% for apoB, and 9% for Lp [a] . External quality control consisted of participation in the Centers for Disease Control and Prevention's Lipid Standardization Program. 41 In addition, a subset of participant sample aliquots was taken from the blood collection tubes, stored at each field center for an additional week, and sent to the laboratory in the subsequent weekly mailing in a blinded fashion, thereby providing a measure of the overall variability of measurement (ie, variability due to storage, shipping, sample processing, transcription, and analyses). The coefficients of variation in these blinded replicates for total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, apoA-I, and Lp[a] were 3.0%, 6.7%, 4.4%, 5.3%, 11.0%, and 16.9%, respectively.
Lp[a] phenotyping was performed as previously described. 13 Specimens containing 25 ^g of Lp[a] protein, based on ELISA measurements, were applied to sodium dodecyl sulfate (SDS)-PAGE gels containing 3.75% acrylamide, 0.10% bisacrylamide, and 0.75% agarose (type C, Behring Diagnostics, La Jolla, Calif). Electrophoresis was performed at 10°C for 18 hours at 25 mA/gel, and electrophoretic transfer of proteins from gel to nitrocellulose was performed for 18 hours at 50 V. Apo[a] polymorphs were localized on the nitrocellulose membrane using IgG purified from rabbit antisera directed against apo[a], followed by detecting the bound IgG with 125 I-protein A (ICN Biomedicals, Inc, Irvine, Calif). Radiolabeled bands were visualized after overnight exposure at -70°C to X-omat XAR5 film (Eastman Kodak Co, Rochester, NY) using a Lightening Plus intensifying screen (DuPont, Wilmington, Del). Apo[a] polymorph molecular weights were estimated using apoB-100 (M r , 512 kD) and cross-linked phosphorylase b (97.4 kD) oligomers (Sigma Chemical Co, St Louis, Mo).
Statistical Methods
Standard unmatched / tests were used to compare mean levels between cases and controls. Because of the very nonnormal distributions of plasma Lp[a] and triglyceride concentrations, the nonparametric rank-sum test was used 42 to compare median levels of these variables between cases and controls. Because of the large number of apo[a] phenotypes relative to the number of individuals in this sample, traditional x 2 goodness-of-fit tests and x 2 tests of independence were inappropriate. A goodness-of-fit test to Hardy-Weinberg expectations was carried out using a computerized permutation algorithm described by Guo and Thompson. 43 Comparisons of apo[a] polymorph and phenotype frequencies between groups (eg, cases versus controls, males versus females) were carried out using a Monte Carlo simulation method to derive probability values for Fisher's Exact Test. 44 The relation between apo[a] polymorph size and plasma Lp[a] concentration was summarized with Spearman's rank correlation. 42 Conditional stepwise logistic regression 4546 was used to identify the set of statistically significant predictor variables. The list of potential predictor variables included sex; age; body mass index; pack-years of cigarette smoking; hypertension status; ethanol consumption; and glucose, insulin, total cholesterol, triglyceride, LDL cholesterol, HDL cholesterol, apoA-I, apoB, and Lp[a] levels. Because this is a cross-sectional study, the dependent variable in the logistic regression equation is the log of the odds of being a carotid case at the time of baseline examination, rather than the log of the odds of developing symptomatic atherosclerotic heart disease. Logistic regression analysis was used rather than discriminant analysis because the model for logistic regression is less restrictive than the linear discriminant model with respect to assumptions. 47 Variable selection was carried out in an ordered manner using a priori considerations. First, the set of significant demographic and anthropometric variables was identified; to this list the set of biochemical measures, such as plasma lipid concentration (excluding Lp[a]) variables, was added. We next tested whether Lp[a] improved our ability to predict prevalent disease, given that the other recognized predictors were already in the model. And finally, we asked whether information about apo[a] polymorphs and phenotypes contributed to our ability to predict disease beyond that afforded by more traditional risk factors. The latter analysis was carried out with and without plasma Lp[a] concentrations in the model. Table 1 shows mean values of cardiovascular risk factors in cases and controls. Despite the selection procedure, cases were 1 year older than controls. Cases also had a higher body mass index, a greater pack-year history of cigarette smoking, and a higher prevalence of hypertension. Cases had significantly greater concentrations of total cholesterol (7.8%), triglyceride (30.8%), LDL cholesterol (14.0%), apoB (13.9%), and Lp[a] protein (32.8%) and decreased levels of HDL cholesterol (13%) and apoA-I (5.9%). The differences in triglyceride and Lp[a] protein remained significant after logarithmic transformation of these variables (data not shown).
Results
Plasma Lipids, Apolipoproteins, and Lp[a] Concentrations in Study Subjects
The range of Lp[a] protein levels was similar in controls (2 to 392 /xg/mL) and cases (4 to 361 yug/mL). In both groups, the distribution of Lp[a] protein levels was highly skewed (skewness: 2.1 in controls and 1.6 in cases). Median Lp[a] protein levels were 51 /ig/mL in cases and 33 /ig/mL in controls (P<.003), and the cumulative frequency distribution curve of Lp[a] protein levels in cases was shifted to the right relative to controls (Fig 1) .
Apo[a] Phenotype Distributions in Controls and Cases
Control subjects demonstrated 39 of the 66 possible apo[a] phenotypes in the system, based on the resolution of 11 different polymorphs. 13 In these subjects, 60 204 (37) 107 (60) 54 (18) 128 (36) 132 (30) 86 (26) 64 (74) Cases, 220 (40) 140 (87) 47 (15) 146 (36) 125 (28) 98 (25) 85 ( 
263).
The observed phenotype frequencies were significantly different from those expected under HardyWeinberg equilibrium (P<.0001 in cases and /5<.0001 in controls). This result agrees with our previous studies 13 and is consistent with the notion that the expression levels of some apo[a] alleles are below the limit of detection. Apo[a] polymorph distributions in cases and controls are shown in Fig 2. The polymorph distributions did not differ between cases and controls, irrespective of whether 1 or 2 polymorphs were counted in those phenotypes defined by a single apo[a] species (P=.35 for counting 1 polymorph and P=35 for counting 2 polymorphs).
Correlation ofApo[a] Phenotype With Lpfa] Protein Levels in Cases and Controls
An (160) 89 (66) 86 (108) 98 (88) 58 (61) 76 (125) 129 (113) 52 (57) 139 17 (6) 57 (62) 18 61 (36) 69 (17) 24 (13) 29 49 (29) 57 (58) 64 (37) 69 62 (34) 41 (29) 74 (52) 60 (19) 42 22 (15) 54 58 (14) 29 (21) 9 ( (42) 151 (150) 199 (128) 111 (94) 75 (46) 106 (55) 109 (137) (24) 100 (66) 42 (9) 27 (19) 52 (43) 104 (31) 49 (43) 70 (65) 
Apofa] Phenotypes as Predictors of Case-Control Status
Conditional logistic regression analysis using a stepwise approach based on a priori considerations (see "Methods") revealed that age, body mass index, prevalence of hypertension, pack-years of cigarette smoking, plasma HDL cholesterol, plasma apoB, and Lp[a] protein concentrations were predictors of prevalent casecontrol status in our study population (Table 4) . As expected, the direction of the relation between each of the predictor variables and the probability of having prevalent disease in this cross-sectional study was positive except for HDL cholesterol, which was negative. There was also no significant difference in the frequency distribution of apo [a] phenotypes between the two groups (P= J 68, Fisher's Exact Test). When the 29 women using hormones were excluded from the analyses, nearly identical results were obtained and none of the conclusions changed. The identical set of predictor variables for prevalent case-control status was identified; apo[a] phenotype did not improve the predictive ability of the logistic model.
Discussion
This study confirms our recent findings in an overlapping but different ARIC Study population that the plasma level of Lp[a] protein is an independent risk factor for intima-media thickening of the carotid arteries in white subjects who are free of symptomatic cardiovascular and cerebrovascular disease. 25 The principal new findings of the present study are (1) tem differs from that of Utermann et al, 12 in that more apo[a] polymorphs are resolved, many of the possible phenotype combinations are missing or infrequently observed. Therefore, we tried to emulate the phenotyping system of Utermann et al by combining adjacent polymorphs into one group, but we were still unable to detect any significant difference in the distributions of phenotypes and polymorphs between cases and controls. Thus, the different methodologies used for phenotyping appear not to account for the lack of phenotypic differences between cases and controls. Further support for this conclusion comes from the Framingham Offspring Study, 52 in which the phenotyping system used here was employed in that study and a higher prevalence of small apo[a] polymorphs was found in patients with CAD than in controls. 
